Amalgent
Delaware LLC · 1 known investors
Amalgent develops combination drugs based on existing medications to improve the safety profile of oral pain therapeutics for the US market. The company is in clinical-stage development focused on pain management.
Founders & leadership
MA
Malcolm A MeynExecutive Officer, Director
ST
Sam TetlowDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$200KraisedApr 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedApr 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Malcolm A MeynExecutive Officer, Director
- Sam TetlowDirector
- Offering amount
- $1M
- Amount sold
- $200K
- First sale
- Apr 2022
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Funding - Business in Delaware | Delaware Prosperity Partnershipchoosedelaware.com · 2023